They now have a $39.00 price target on the stock. They wrote, “We anticipate data from the Ph2 tazemetostat trial in NHL will be the main driver of the stock.
They now have a $39.00 price target on the stock. They wrote, “We anticipate data from the Ph2 tazemetostat trial in NHL will be the main driver of the stock.